The word 'validated' is the real fight in U.S. drug testing

Every industry keeps a word that gates who gets to be heard. In U.S. drug testing, that word is "validated," and the fight over it is now in court.

Valisure, the private Connecticut lab that has spent years flagging impurities in widely used medicines from Zantac to benzoyl peroxide acne products, filed suit this week against U.S. Pharmacopeia, the independent body that writes America's drug-quality standards. The target is a 2023 USP white paper that Valisure alleged characterized its methods as "unvalidated" and warned of "misleading results" and "unnecessary concern."

That single word does most of the work. As the Valisure episode illustrates, a "validated" method gets cited in FDA filings, in recall decisions, and on front pages; an "unvalidated" one gets dismissed as advocacy. Valisure's complaint argues USP is using the label to defend its own methods and the system those methods anchor. USP declined to comment beyond the litigation.

Valisure's complaint frames the arrangement this way: in U.S. drug testing, the standards-setter is also the referee, and the referee's methods are by definition the validated ones. Anyone testing outside that frame has to argue for standing before arguing about chemistry. Valisure's high-profile benzene findings have drawn both regulatory attention and an FDA rebuke, so the dispute is not abstract.

The question the suit puts on the docket is structural: who licenses the word "validated" in American drug testing, and who has standing to challenge that license when impurity findings surface.